- Inhibitory Selectivity
|Catalog No.||Product Name||Solubility(25°C)|
|S1258||Prasugrel||<1 mg/mL||30 mg/mL||7 mg/mL|
|S1415||Clopidogrel||78 mg/mL||83 mg/mL||46 mg/mL|
|S2855||MRS 2578||<1 mg/mL||42 mg/mL||<1 mg/mL|
|S4079||Ticagrelor||<1 mg/mL||100 mg/mL||53 mg/mL|
|S1984||Ticlopidine HCl||4 mg/mL||1 mg/mL||1 mg/mL|
|S8725||A-804598||<1 mg/mL||63 mg/mL||6 mg/mL|
|S3737||Cangrelor Tetrasodium||100 mg/mL||2 mg/mL||<1 mg/mL|
|S8519||A-317491||<1 mg/mL||100 mg/mL||100 mg/mL|
|S7705||A-438079 HCl||61 mg/mL||61 mg/mL||20 mg/mL|
|S4637||Prasugrel Hydrochloride||<1 mg/mL||46 mg/mL||9 mg/mL|
- P2 Receptor Inhibitors (10)
- New P2 Receptor Products
|Catalog No.||Information||Product Use Citations||Product Validations|
Prasugrel is a thienopyridine ADP receptor (P2Y12) antagonist, used for the reduction of thrombotic cardiovascular events.
Clopidogrel is an oral, thienopyridine class antiplatelet agent.
(A) HPLC glycan traces of IgG recovered from joint after K/BxN and PBS or B4ST6Fc treatment with or without clopidogrel. (B) Ratios of monosialylated and agalactosylated glycans (S1/G0) from IgG described in (A).
MRS2578 is a potent P2Y6 receptor antagonist with IC50 of 37 nM, exhibits insignificant activity at P2Y1, P2Y2, P2Y4,and P2Y11 receptors.
Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist with Ki of 2 nM.
Effect of antiplatelet drugs on platelet aggregation in healthy individuals. Samples from healthy individuals were preincubated with anti-platelet drugs (n = 3). Curves and columns show mean platelet aggregation and the relationship between platelet aggregation and drug concen-tration. Bars represent standard deviations. *P < 0.05 as compared with platelet aggregation with the same agonist but no drugs added; pairedStudent’s t-test. (A-C) The drugs tested were abciximab (A), ticagrelor (B), and vorapaxar (C).
Ticlopidine HCl is an P2 receptor inhibitor against ADP-induced platelet aggregation with IC50 of ~2 μM.
A-804598 is a selective P2X7R antagonist with high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) P2X7 receptors.
Cangrelor is a potent, competitive P2Y12 receptor inhibitor that is administered by intravenous infusion and rapidly achieves near complete inhibition of ADP-induced platelet aggregation.
A-317491 is a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors with Ki values of 22 nM and 9 nM for human P2X3 and P2X2/3 receptors.
A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
Prasugrel hydrochloride is a piperazine derivative and pletelet aggregation inhibitor that is used to prevent thrombosis in patients with acute coronary syndrome.